CAM
AKBA icon

ClariVest Asset Management’s Akebia Therapeutics AKBA Stock Holding History

ClariVest Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-69,100
Closed -$524K – 773
2020
Q1 		$524K Sell
69,100
-30,000
-30% -$233K 0.02% 395
2019
Q4 		$626K Sell
99,100
-700
-0.7% -$3.33K 0.01% 404
2019
Q3 		$391K Sell
99,800
-900
-0.9% -$3.86K 0.01% 436
2019
Q2 		$487K Buy
100,700
+56,000
+125% +$319K 0.01% 369
2019
Q1 		$366K Buy
+44,700
New +$307K 0.01% 482

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ClariVest Asset Management's AKBA Position: Q2 2020 in Review

ClariVest Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 69,100 shares — an estimated $524K sold.

ClariVest Asset Management first reported a position in AKBA in Q1 2019 and held it in 5 quarters. The position peaked at $626K in Q4 2019. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • ClariVest Asset Management reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • ClariVest Asset Management sold 69,100 Akebia Therapeutics shares in Q2 2020, an estimated $524K.
  • ClariVest Asset Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 5 quarters.
  • ClariVest Asset Management's Akebia Therapeutics position peaked at $626K in Q4 2019.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on ClariVest Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.